Clinical trials: Drug Eluting Stents
Restenosis, Myocardial Infarction
Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis
Evidence supporting use of bioabsorbable polymer drug eluting stents (BP-DES) is uncertain. Thus the investigators planned a meta-analysis to compare outcomes of BP-DES versus PP-DES in obstructive coronary artery disease.
- Trial name
- NCT01466634
- Testing
- percutaneous coronary intervention with stent
- Where
- Italy
- Volunteers
- 6,221 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
In Stent Restenosis
Focal In-stent Restenosis After Drug-Eluting Stent
To evaluate the optimal management of focal in-stent restenosis after drug-eluting stent implantation with sirolimus-eluting implantation versus cutting balloon angioplasty
- Trial name
- FOCUS (NCT00485004)
- Testing
- Cutting balloon, Sirolimus-eluting stent
- Where
- 15 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Study to Test the Efficacy and Safety of Drug Eluting vs. Bare-Metal Stents for Saphenous Vein Graft Interventions
Prospective multicenter controlled randomized trial to compare the safety and efficacy of drug eluting vs. bare metal stents in percutaneous coronary interventions of saphenous vein grafts.
- Trial name
- BASKET-SAVAGE (NCT00595647)
- Testing
- Drug eluting stent, Bare metal stent
- Where
- 5 sites in Denmark, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- University Hospital, Basel, Switzerland
Coronary Heart Disease
Economic Evaluation German Drug-Eluting Stent Registry
Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients.
- Trial name
- NCT00866398
- Volunteers
- 3,973 people
- Sponsor
- Charite University, Berlin, Germany
Arterial Occlusive Diseases
YUKON-drug-eluting Stent Below The Knee - Randomised Double-blind Study
The purpose of this study is to compare the effectiveness of the treatment with balloon-expandable YUKON-BTX-Sirolimus-eluting stent over the treatment with YUKON-BTX uncoated stent in patients with ischemic infrapopliteal…
- Trial name
- YUKON-BTK (NCT00664963)
- Testing
- Implantation of YUKON Sirolimus-eluting Stent, Implantation of YUKON Stent (uncoated)
- Where
- 3 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Herz-Zentrums Bad Krozingen
Coronary Artery Disease
DEBSCAN-IVL. Drug Eluting Balloon or Drug Eluting Stent to Treat CAlcified Nodules After IntraVascular Lithotripsy.
International, investigator-driven, multicenter, open-label, prospective randomized controlled trial where patients with de novo lesions due to calcified nodules (CN) were randomized to drug eluting balloon (DEB) or drug eluting…
- Trial name
- DEBSCAN-IVL (NCT06657833)
- Testing
- Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting balloon, Percutaneous coronary intervention of a calcified nodule with intravascular lithotripsy followed by drug eluting stent
- Where
- 15 sites in Netherlands, Spain
- Volunteers
- 128 people
- Sponsor
- Fundación EPIC
Coronary Calcification
DCB vs DES for Severe Coronary Calcification After Optimal Modification Assessed by QFR
The goal of this clinical trial is to learn if the short and long term effect of drug coated balloon (DCB) is non-inferior to drug eluting stent (DES) in patients with severe coronary calcification after optimal calcium…
- Trial name
- NCT07277114
- Testing
- rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), Intravascular Lithotripsy (IVL)
- Where
- China
- Volunteers
- 656 people
- Sponsor
- Shanghai Zhongshan Hospital
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary…
- Trial name
- NCT05782777
- Testing
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg)
- Where
- South Korea
- Volunteers
- 4,310 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Self-apposing Stentys Stents Registry
Self-apposing, drug-eluting Stentys coronary stents represent a valuable tool for the treatment of coronary artery stenosis. Their ability to adapt to widely varying vessel calibers and to auto-expand after their release to…
- Trial name
- SPARTA (NCT02784405)
- Where
- 14 sites in Italy, Malaysia and 1 more
- Volunteers
- 100 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Acute Coronary Syndrome, Acute Myocardial Infarction
Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome
The investigators hypothesized that ticagrelor may enhance endothelial healing after DES implantation by increasing adenosine concentrations by the inhibition of adenosine uptake into erythrocytes, compared to clopidogrel.
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina (Intermediate Coronary Syndrome)
- Trial name
- NCT02037412
- Testing
- Ticagrelor, Clopidogrel
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Yonsei University
Coronary Artery Disease
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
This study is a prospective, multi-center single arm registry trial, planning to enroll 785 subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year after index procedure.
- Trial name
- NCT04179045
- Testing
- The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Where
- 5 sites in China
- Volunteers
- 785 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Coronary Artery Disease
Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)
The purpose of this study is to compare the safety and effectiveness of drug-eluting stent implantation compared to optimal medical treatment in patients with chronic total occlusion.
- Trial name
- NCT01078051
- Testing
- Cypher, xience, Endeavor, Taxus, optimal medical therapy
- Where
- 26 sites in India, Indonesia and 3 more
- Volunteers
- 840 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events
1. To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents. 2. To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or…
- Trial name
- ASAN-VERIFY (NCT01183754)
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- CardioVascular Research Foundation, Korea
In-stent Restenosis
Target Vessel Failure After Laser Assisted Percutaneous Angioplasty Versus Balloon-based Treatment for Drug Eluting In-stent Restenosis
Stent restenosis (ISR) is an increasingly common problem; in fact, approximately 10% of coronary angioplasty procedures involve the treatment of a previously implanted stent.
- Trial name
- SONIC (NCT07382154)
- Where
- Italy
- Volunteers
- 1,260 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Heart Disease, Acute Coronary Syndrome
A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography
BioFreedom™ is the world's first polymer-free drug-coated stent (DCS), utilizing a proprietary microstructured surface technology.
- Trial name
- NCT07230847
- Testing
- BioFreedom™, Xience
- Where
- China
- Volunteers
- 60 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease, Cardiovascular Diseases
Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent
The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia
- Trial name
- IRIS SynergyXD (NCT05044273)
- Testing
- Synergy XD stent or Synergy Megatron™ Stent
- Where
- 23 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Jung-min Ahn
Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled.
- Trial name
- CHAMPIONSHIP (NCT06410313)
- Testing
- ChampioNIR Ridaforolimus Eluting Peripheral Stent System
- Where
- 7 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- Medinol Ltd.
ST Elevation Myocardial Infarction (STEMI), Acute Coronary Syndromes (ACS)
A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
This is a single-center, retrospective, propensity-score-matched observational study. It aims to compare the rate of immediate slow-flow or no-reflow after percutaneous coronary intervention (PCI) between drug-coated balloon…
- Trial name
- STEMI-DCB (NCT07806370)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES)
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Xijing Hospital